Study presents new persistence analysis of FINTEPLA, evaluating the efficacy and tolerability of FINTEPLA over a span of 12 months1 Real-world data looks into the need for resources to support caregivers – both parents and siblings – of people living with developmental and epileptic encephalopathies such as Dravet and Lennox-Gastaut syndromes in the transition from […]
Median time to return to full baseline function occurred within 90 minutes following outpatient treatment with NAYZILAM® (midazolam) nasal spray, with a.